The Janus faces of CD40 in cancer

被引：53

作者：

Loskog, Angelica S. I. ^{[2
]}

Eliopoulos, Aristides G. ^{[1
,3
]}

机构：

[1] Univ Crete, Div Basic Sci, Sch Med, Mol & Cellular Biol Lab, Iraklion, Crete, Greece

[2] Uppsala Univ, Div Clin Immunol, Rudbeck Lab, Uppsala, Sweden

[3] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion, Crete, Greece

来源：

SEMINARS IN IMMUNOLOGY | 2009年 / 21卷 / 05期

关键词：

CD40; Cancer; Pathogenesis; Therapy; CHRONIC LYMPHOCYTIC-LEUKEMIA; NF-KAPPA-B; BURKITT-LYMPHOMA CELLS; LIGAND GENE-THERAPY; HUMAN BREAST-CANCER; ENDOTHELIAL-CELLS; CARCINOMA-CELLS; SOLUBLE CD40; PHASE-I; CONSTITUTIVE ACTIVATION;

D O I：

10.1016/j.smim.2009.07.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

CD40 is a TNF receptor family member that is widely recognized for its prominent role in immune regulation and homeostasis. Expression of CD40 is not restricted to normal lymphoid cells but is also evident in the majority of haemopoietic and epithelial malignancies where it has been implicated in oncogenic events. Accumulating evidence, however, suggests that the CD40 pathway can be exploited for cancer therapy by virtue of its ability to stimulate the host anti-tumor immune response, normalize the tumor microenvironment and directly suppress the growth of CD40-positive tumors. Here, we provide an overview of the multifaceted functions of the CD40 pathway in cancer and its emerging role in the treatment of malignancy. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：301 / 307

页数：7

共 82 条

[1] CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection [J].

Afford, SC ;

Randhawa, S ;

Eliopoulos, AG ;

Hubscher, SG ;

Young, LS ;

Adams, DH .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (02) :441-446

[2]

Andersen NS, 2000, BLOOD, V96, P2219

[3] Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand [J].

Baker, MP ;

Eliopoulos, AG ;

Young, LS ;

Armitage, RJ ;

Gregory, CD ;

Gordon, J .

BLOOD, 1998, 92 (08) :2830-2843

[4] Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth [J].

Baxendale, AJ ;

Dawson, CW ;

Stewart, SE ;

Mudaliar, V ;

Reynolds, G ;

Gordon, J ;

Murray, PG ;

Young, LS ;

Eliopoulos, AG .

ONCOGENE, 2005, 24 (53) :7913-7923

[5] Rapid CD40-mediated rescue from CD95-induced apoptosis requires TNFR-associated factor-6 and PI3K [J].

Benson, Rebecca J. ;

Hostager, Bruce S. ;

Bishop, Gail A. .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (09) :2535-2543

[6] Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia [J].

Biagi, E ;

Rousseau, R ;

Yvon, E ;

Schwartz, M ;

Dotti, G ;

Foster, A ;

Havlik-Cooper, D ;

Grilley, B ;

Gee, A ;

Baker, K ;

Carrum, G ;

Rice, L ;

Andreeff, M ;

Popat, U ;

Brenner, M .

CLINICAL CANCER RESEARCH, 2005, 11 (19) :6916-6923

[7]

Bishop GA, 2007, ADV EXP MED BIOL, V597, P131

[8]

Bugajska U, 2002, J NATL CANCER I, V94, P1381

[9] Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis [J].

Bussolati, B ;

Russo, S ;

Deambrosis, I ;

Cantaluppi, V ;

Volpe, A ;

Ferrando, U ;

Camussi, G .

INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (06) :654-661

[10] CD40 LIGAND AND ITS ROLE IN X-LINKED HYPER-IGM SYNDROME [J].

CALLARD, RE ;

ARMITAGE, RJ ;

FANSLOW, WC ;

SPRIGGS, MK .

IMMUNOLOGY TODAY, 1993, 14 (11) :559-564

← 1 2 3 4 5 6 7 8 9 →